Cogent Biosciences, Inc. Common Stock (COGT) Financials

Key financial figures for Cogent Biosciences, Inc. Common Stock (Q2 2026).

Cogent Biosciences reported a $96.4 million Q2 2026 net loss on $792.3 million in cash, cash equivalents and marketable securities, and said existing cash plus $73.6 million in post-quarter ATM proceeds should fund operations into late 2028, including through anticipated FDA approvals of bezuclastinib. R&D expense rose to $70.8 million (vs $62.2 million in Q2 2025), driven by the SUMMIT, PEAK and APEX clinical programs, bezuclastinib regulatory activity, early-stage pipeline investment, and pre-approval manufacturing costs. G&A expense rose to $31.8 million (vs $13.4 million in Q2 2025), driven by commercial-readiness hiring and infrastructure ahead of a potential bezuclastinib launch. Net loss was $96.4 million, up from $73.5 million in Q2 2025. On the outlook: Management stated that existing cash, cash equivalents and marketable securities, together with $73.6 million in gross ATM proceeds raised after quarter-end, are expected to be sufficient to fund operating expenses and capital expenditures into late 2028, including through potential FDA approvals of bezuclastinib for GIST, NonAdvSM and AdvSM and early commercial launch activities. Figures are for Q2 2026, as Cogent Biosciences reported them.

Revenue

$0

Net Income

-$96M

EPS

$-0.52

Total Assets

$835M

Operating Cash Flow

-$77M

Full income statement, balance sheet and cash flow for Cogent Biosciences, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.